The combination of vidutolimod and nivolumab demonstrated activity in a phase 2 trial of patients with high-risk, resectable melanoma, according to researchers. They reported these findings in Cancer Cell.
Melanoma News
TIL Therapy Uses the Body’s Own Cells to Attack Cancer Cells in Melanoma
Tumor-infiltrating lymphocyte (TIL) therapy is a promising new approach to cancer therapy that harnesses the body’s own immune system to treat diseases like melanoma, a type of skin disease, an expert said.
Yeppoon family shares devastating melanoma journey in hope it saves lives
Lyell Duffy thought he had pulled a muscle at work when he began experiencing back pain.
Low Neutrophil-Lymphocyte Ratio Linked to Better Survival in Some Melanoma Cases
Baseline neutrophil-lymphocyte ratio (NLR) is a significant predictor of disease progression and overall survival (OS) in patients with metastatic melanoma undergoing programmed cell death receptor-1 (PD-1) and its ligand (PD-L1) blockade therapy, according to study results published in Melanoma Research.